KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Assets Average (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Assets Average for 12 consecutive years, with $620.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 24.05% to $620.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $620.5 million, a 24.05% decrease, with the full-year FY2025 number at $715.7 million, down 18.81% from a year prior.
  • Assets Average was $620.5 million for Q4 2025 at Xenon Pharmaceuticals, down from $641.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $941.9 million in Q1 2024 to a low of $239.9 million in Q1 2021.
  • A 5-year average of $660.6 million and a median of $705.6 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 193.69% in 2022, then dropped 25.45% in 2025.
  • Xenon Pharmaceuticals' Assets Average stood at $418.2 million in 2021, then soared by 82.93% to $765.0 million in 2022, then increased by 6.92% to $817.9 million in 2023, then fell by 0.11% to $817.0 million in 2024, then dropped by 24.05% to $620.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Assets Average are $620.5 million (Q4 2025), $641.1 million (Q3 2025), and $708.8 million (Q2 2025).